FIELD: medicine; pharmacology.
SUBSTANCE: offered are compositions of formula 1 , where PG represents hydrogen or formyl group. R1 and R2 together with nitrogen atom to which they are attached, form heterocycle chosen from piperidine or morpholine and their pharmaceutically acceptable salts.
EFFECT: high haemostatic activity.
8 ex
Title | Year | Author | Number |
---|---|---|---|
HAEMOSTATIC MEDICATION BASED ON SYNTHETIC TRIPEPTIDE PLASMIN INHIBITOR | 2014 |
|
RU2550945C1 |
METHOD FOR DETERMINING TISSULAR PLASMINOGEN ADJUVANT | 2003 |
|
RU2252421C1 |
HEMOSTATIC SPONGE AND METHOD OF ITS PRODUCTION | 2016 |
|
RU2628809C1 |
HAEMOSTATIC SPONGE AND METHOD FOR ITS PREPARATION | 2016 |
|
RU2618896C1 |
HEMOSTATIC SOLUTION BASED ON SULFUSATED POLYSACCHARIDES AND THE HEMOSTATIC SPONGES PRODUCTION FROM THIS SOLUTION (OPTIONS) | 2017 |
|
RU2652270C1 |
PROCOAGULANT PEPTIDES, THEIR DERIVATIVES AND THEIR APPLICATION | 2012 |
|
RU2635510C2 |
HEMOSTATIC COATING IN THE FORM OF POWDER | 2017 |
|
RU2660582C1 |
METHOD OF DETERMINING PLASMINOGEN AND PLASMIN INHIBITORS LEVELS IN BLOOD PLASMA | 1998 |
|
RU2121690C1 |
THROMBOLYTICS FOR INTRAVASCULAR THROMBI | 2020 |
|
RU2822136C1 |
METHOD OF DETERMINING PLASMIN FIBRINOLYTIC ACTIVITY IN BLOOD | 1996 |
|
RU2125266C1 |
Authors
Dates
2008-12-20—Published
2006-10-12—Filed